Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Pomalidomide, rituximab, and orelabrutinib in combination with polatuzumab vedotin for newly diagnosed diffuse large B-cell lymphoma in elderly, unfit, or frail patients:a prospective phase II study

Changju Qu, Nana Ping, Qian Zhu, Junhong Li, Xiao Zhang, Fan Xia, Rui Zou, Siyun He, Depei Wu, Zhengming Jin

Blood (2025) 146 (Supplement 1): 1912.

https://doi.org/10.1182/blood-2025-1912

Published: 2025

Journal Articles

Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma in Chinese population: A single-arm, multicenter, phase 2 trial

Blood (2025) 146 (Supplement 1): 1796.

https://doi.org/10.1182/blood-2025-1796

Published: 2025

Journal Articles

Chidamide in combination with brentuximab vedotin for CD30+ peripheral T-cell lymphoma in patients ineligible for chemotherapy: a prospective phase II study

Changju Qu, Nana Ping, Danqing Kong, Qian Zhu, Junhong Li, Xiao Zhang, Fan Xia, Rui Zou, Siyun He, Depei Wu, Zhengming Jin

Blood (2025) 146 (Supplement 1): 7167.

https://doi.org/10.1182/blood-2025-7167

Published: 2025

Journal Articles

Dual epigenetic modulation with obinutuzumab/liposomal mitoxantrone in refractory or Relapsed Diffuse large B-cell lymphoma patients post-salvage therapy: A phase II study

Changju Qu, Nana Ping, Rui Zou, Jiajie He, Qian Zhu, Junhong Li, Xiao Zhang, Fan Xia, Danqing Kong, Siyun He, Depei Wu, Zhengming Jin

Blood (2025) 146 (Supplement 1): 5468.

https://doi.org/10.1182/blood-2025-5468

Published: 2025

Journal Articles

Efficacy and Safety of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Relapse/Refractory Non-Hodgkin's Lymphoma: Real-World Data in Chinese Population

Blood (2024) 144 (Supplement 1): 5115.

https://doi.org/10.1182/blood-2024-207186

Published: 2024

Journal Articles

Pomalidomide, Rituximab, Orelabrutinib, and Minichop-like (PRO-miniCHOP) in Elderly Patients with Newly Diagnosed Diffuse Large-B Cell Lymphoma: Updated Results from a Phase II Study

Nana Ping, Changju Qu, Jiajie He, Hailing Liu, Rui Zou, Qian Zhu, Xiao Zhang, Depei Wu, Zhengming Jin

Blood (2024) 144 (Supplement 1): 6479.

https://doi.org/10.1182/blood-2024-198588

Published: 2024

Journal Articles

A Phase II Study of Dual Epigenetic Agents Plus Obinutuzumab-Mitoxantrone Liposome in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients Failure of Salvage Immunochemotherapy

Changju Qu, Nana Ping, Rui Zou, Jiajie He, Qian Zhu, Xiao Zhang, Junhong Li, Fan Xia, Lingzi Yu, Depei Wu, Zhengming Jin

Blood (2024) 144 (Supplement 1): 6499.

https://doi.org/10.1182/blood-2024-201151

Published: 2024

Journal Articles

Zr Study: A Prospective Phase II Study of Zanubrutinib-Rituximab Chemo-Free Therapy with or without Autologous Stem Cell Transplantation in Newly Diagnosed Mantle Cell Lymphoma

Changju Qu, Nana Ping, Rui Zou, Jiajie He, Qian Zhu, Xiao Zhang, Fan Xia, Danqing Kong, Depei Wu, Zhengming Jin

Blood (2023) 142 (Supplement 1): 1658.

https://doi.org/10.1182/blood-2023-179599

Published: 2023

Journal Articles

Addition of Chidamide to a Sandwich Protocol, Pegaspargase, Gemcitabine and Oxaliplatin Chemotherapy Combined with Radiotherapy, As First-Line Treatment in Early Stage NK/T-Cell Lymphoma: Real World Outcomes in a Retrospective Study

Fan Xia, Nana Ping, Qi Bao, Rui Zou, Qian Zhu, Xiao Zhang, Depei Wu, Zhengming Jin, Changju Qu

Blood (2023) 142 (Supplement 1): 6202.

https://doi.org/10.1182/blood-2023-177828

Published: 2023

Journal Articles

Pomalidomide, Rituximab, Orelabrutinib, and Minichop-like (PRO-miniCHOP) in Elderly Patients with Newly Diagnosed Diffuse Large-B Cell Lymphoma: Preliminary Results from a Phase II Study

Nana Ping, Changju Qu, Jiajie He, Hailing Liu, Rui Zou, Qian Zhu, Xiao Zhang, Depei Wu, Zhengming Jin

Blood (2023) 142 (Supplement 1): 6238.

https://doi.org/10.1182/blood-2023-181350

Published: 2023

Journal Articles

Decitabine in Combination with Fludarabine and Cyclophosphamide As Lymphodepletion Regimen Followed By CD19/CD22 Bispecific Targeted CAR-T Therapy Significantly Improves Survival in Relapsed/Refractory B-ALL Patients: A Pilot Study

Yunju Ma, Changju Qu, Haiping Dai, Sining Liu, Qingya Cui, Wei Cui, Jia Yin, Liqing Kang, Xiaying Lian, Huiying Qiu, Xiaming Zhu, Lei Yu, Depei Wu, Xiaowen Tang

Blood (2021) 138 (Supplement 1): 1754.

https://doi.org/10.1182/blood-2021-152041

Published: 2021

Journal Articles

Dual Epigenetic Agents Plus Rituximab-Gemcitabine-Oxaliplatin As a Salvage Treatment in Relapsed/Refractory Diffuse Large B Cell Lymphoma Patients

Changju Qu, PhD, Nana Ping, MD, PhD, Danqing Kong, MD, Fan Xia, MD, Depei Wu, MD PhD, Zhengming Jin, MD

Blood (2019) 134 (Supplement_1): 5338.

https://doi.org/10.1182/blood-2019-128111

Published: 2019

Journal Articles

Maintenance Therapy with Decitabine after Allogeneic Hematopoietic Stem Cell Transplantation to Prevent Relapse of High Risk Acute Myeloid Leukemia

Yunju Ma, Changju Qu, PhD, Haiping Dai, Jia Yin, Zheng Li, Jia Chen, Huiying Qiu, Aining Sun, PhD, Miao Miao, Chengcheng Fu, Zhengming Jin, MD, Xiaming Zhu, Depei Wu, MD PhD, Xiaowen Tang

Blood (2019) 134 (Supplement_1): 3306.

https://doi.org/10.1182/blood-2019-124033

Published: 2019

Journal Articles

Successful Treatment of Chimeric Antigen Receptor T Cell Therapy in Refractory or Relapsed Acute Leukemia Patients with TP53 alterations

Changju Qu, PhD, Jia Yin, Liqing Kang, Zheng Li, Haiping Dai, Xiaming Zhu, Lei Yu, Depei Wu, MD PhD, Xiaowen Tang

Blood (2019) 134 (Supplement_1): 3822.

https://doi.org/10.1182/blood-2019-128013

Published: 2019

Journal Articles

Tandem CAR T Cells Targeting CD19 and CD22 Is a Safe and Highly Efficacious Treatment for Relapse/ Refractory ALL Patients

Xiaowen Tang, Liqing Kang, Wei Qi, Wei Cui, Haiping Dai, Zheng Li, Jia Yin, Changju Qu, PhD, Ting Xu, Xiaming Zhu, Lei Yu, MD PhD, Depei Wu, MD PhD

Blood (2019) 134 (Supplement_1): 1338.

https://doi.org/10.1182/blood-2019-127890

Published: 2019

Journal Articles

Radiotherapy Priming Chimeric Antigen Receptor T Cell Therapy Is a Safe and Promising Approach in Relapsed/Refractory Diffuse Large B Cell Lymphoma Patients with High Tumor Burden

Changju Qu, MD, PhD, Nana Ping, MD, PhD, Qian Wu, MD, Liqing Kang, Fan Xia, MD, Lei Yu, Depei Wu, Zhengming Jin

Blood (2018) 132 (Supplement 1): 2961.

https://doi.org/10.1182/blood-2018-99-113979

Published: 2018

Journal Articles

Smoothened Stabilizes and Protects TRAF6 from Proteosomal Degradation: A Novel Non-Canonical Role of Smoothened with Implications in Lymphoma Biology

Changju QU, MDPhD, Amineh Vaghefi, MD, Kranthi Kunkalla, MS, Jennifer R Chapman, MD, Yadong Liu, MD, Marzenna Blonska, PhD, Juan Pablo Alderuccio, MD, Leon Bernal-Mizrachi, MD, Izidore S Lossos, MD, Ralf Landgraf, PhD, Francisco Vega, MD PhD

Blood (2017) 130 (Supplement 1): 646.

https://doi.org/10.1182/blood.V130.Suppl_1.646.646

Published: 2017

Journal Articles

Smoothened (SMO) Is an Adaptor Protein That Recruits TRAF6 and Phospholipase C Gamma 2 (PLCg2) to Enhance the Activation of NF-Kb Signaling Pathway

Nitin Agarwal, PhD, Chae Hwa Kim, MD, Kranthi Kunkalla, MS, Gloria Yang, Youley Tjendra, MD, Yadong Liu, MD, Changju Qu, MDPhD, Francisco Vega, MD PhD

Blood (2015) 126 (23): 3907.

https://doi.org/10.1182/blood.V126.23.3907.3907

Published: 2015

Journal Articles

Transcriptional Regulation Of GLI1 , Potential New Therapeutic Target For Diffuse Large B-Cell Lymphoma

Nitin K Agarwal, PhD, Kranthi Kunkalla, MS, David H Hawke, PhD, Yadong Liu, MD, Changju Qu, MD PhD, Francisco Vega, MD, PhD

Blood (2013) 122 (21): 2513.

https://doi.org/10.1182/blood.V122.21.2513.2513

Published: 2013

Journal Articles

Trimeric G protein-CARMA1 axis links smoothened, the hedgehog receptor transducer, to NF-κB activation in diffuse large B-cell lymphoma

Changju Qu, Yadong Liu, Kranthi Kunkalla, Rajesh R. Singh, Marzenna Blonska, Xin Lin, Nitin Kumar Agarwal, Francisco Vega

Blood (2013) 121 (23): 4718–4728.

https://doi.org/10.1182/blood-2012-12-470153

Published: 2013

Includes: Supplemental data

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Pomalidomide, rituximab, and orelabrutinib in combination with polatuzumab vedotin for newly diagnosed diffuse large B-cell lymphoma in elderly, unfit, or frail patients:a prospective phase II study

Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma in Chinese population: A single-arm, multicenter, phase 2 trial

Chidamide in combination with brentuximab vedotin for CD30+ peripheral T-cell lymphoma in patients ineligible for chemotherapy: a prospective phase II study

Dual epigenetic modulation with obinutuzumab/liposomal mitoxantrone in refractory or Relapsed Diffuse large B-cell lymphoma patients post-salvage therapy: A phase II study

Efficacy and Safety of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Relapse/Refractory Non-Hodgkin's Lymphoma: Real-World Data in Chinese Population

Pomalidomide, Rituximab, Orelabrutinib, and Minichop-like (PRO-miniCHOP) in Elderly Patients with Newly Diagnosed Diffuse Large-B Cell Lymphoma: Updated Results from a Phase II Study

A Phase II Study of Dual Epigenetic Agents Plus Obinutuzumab-Mitoxantrone Liposome in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients Failure of Salvage Immunochemotherapy

Zr Study: A Prospective Phase II Study of Zanubrutinib-Rituximab Chemo-Free Therapy with or without Autologous Stem Cell Transplantation in Newly Diagnosed Mantle Cell Lymphoma

Addition of Chidamide to a Sandwich Protocol, Pegaspargase, Gemcitabine and Oxaliplatin Chemotherapy Combined with Radiotherapy, As First-Line Treatment in Early Stage NK/T-Cell Lymphoma: Real World Outcomes in a Retrospective Study

Pomalidomide, Rituximab, Orelabrutinib, and Minichop-like (PRO-miniCHOP) in Elderly Patients with Newly Diagnosed Diffuse Large-B Cell Lymphoma: Preliminary Results from a Phase II Study

Decitabine in Combination with Fludarabine and Cyclophosphamide As Lymphodepletion Regimen Followed By CD19/CD22 Bispecific Targeted CAR-T Therapy Significantly Improves Survival in Relapsed/Refractory B-ALL Patients: A Pilot Study

Dual Epigenetic Agents Plus Rituximab-Gemcitabine-Oxaliplatin As a Salvage Treatment in Relapsed/Refractory Diffuse Large B Cell Lymphoma Patients

Maintenance Therapy with Decitabine after Allogeneic Hematopoietic Stem Cell Transplantation to Prevent Relapse of High Risk Acute Myeloid Leukemia

Successful Treatment of Chimeric Antigen Receptor T Cell Therapy in Refractory or Relapsed Acute Leukemia Patients with TP53 alterations

Tandem CAR T Cells Targeting CD19 and CD22 Is a Safe and Highly Efficacious Treatment for Relapse/ Refractory ALL Patients

Radiotherapy Priming Chimeric Antigen Receptor T Cell Therapy Is a Safe and Promising Approach in Relapsed/Refractory Diffuse Large B Cell Lymphoma Patients with High Tumor Burden

Smoothened Stabilizes and Protects TRAF6 from Proteosomal Degradation: A Novel Non-Canonical Role of Smoothened with Implications in Lymphoma Biology

Smoothened (SMO) Is an Adaptor Protein That Recruits TRAF6 and Phospholipase C Gamma 2 (PLCg2) to Enhance the Activation of NF-Kb Signaling Pathway

Transcriptional Regulation Of GLI1 , Potential New Therapeutic Target For Diffuse Large B-Cell Lymphoma

Trimeric G protein-CARMA1 axis links smoothened, the hedgehog receptor transducer, to NF-κB activation in diffuse large B-cell lymphoma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only